This review highlights the need to address concerns regarding cardiotoxic effects associated with HER2 targeted therapies such as trastuzumab.
No takes yet. Share an insight, caveat, or question.
Emphasizes the necessity of vigilant cardiac monitoring during HER2-targeted breast cancer treatment; leaves.
Florido et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: